Validation of a commercially available SARS-CoV-2 serological Immunoassay
View ORCID ProfileBenjamin Meyer, Giulia Torriani, Sabine Yerly, Lena Mazza, Adrien Calame, Isabelle Arm-Vernez, Gert Zimmer, Thomas Agoritsas, Jérôme Stirnemann, Hervé Spechbach, Idris Guessous, Silvia Stringhini, Jérôme Pugin, Pascale Roux-Lombard, Lionel Fontao, Claire-Anne Siegrist, Isabella Eckerle, Nicolas Vuilleumier, Laurent Kaiser, for the Geneva Center for Emerging Viral Diseases
doi: https://doi.org/10.1101/2020.05.02.20080879
Benjamin Meyer
1Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
Giulia Torriani
2Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland
Sabine Yerly
3Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
Lena Mazza
3Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
Adrien Calame
4Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland
Isabelle Arm-Vernez
3Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
Gert Zimmer
5Institute of Virology and Immunology (IVI), Mittelhäusern, Switzerland
6Department of Infectious Diseases and Pathobiology (DIP), Vetsuisse Faculty, University of Bern, Bern, Switzerland
Thomas Agoritsas
7Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland
8Department of Health Research Methods, Evidence, and Impact, Hamilton, Ontario, Canada
Jérôme Stirnemann
7Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland
Hervé Spechbach
9Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
Idris Guessous
9Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
Silvia Stringhini
9Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
10Unit of Population Epidemiology, Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
Jérôme Pugin
11Division of Intensive Care, Geneva University Hospitals, Geneva, Switzerland
Pascale Roux-Lombard
12Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Geneva University, Geneva, Switzerland
Lionel Fontao
13Division of Dermatology and of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
Claire-Anne Siegrist
1Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
Isabella Eckerle
2Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland
4Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland
14Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland
Nicolas Vuilleumier
12Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Geneva University, Geneva, Switzerland
15Division of Laboratory Medicine, Department of Medicine, Faculty of Medicine, Geneva, Switzerland
Laurent Kaiser
3Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
4Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland
14Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland
Data Availability
Data will be made available upon reasonable request or after accepted publication of the manuscript.
Posted May 06, 2020.
Validation of a commercially available SARS-CoV-2 serological Immunoassay
Benjamin Meyer, Giulia Torriani, Sabine Yerly, Lena Mazza, Adrien Calame, Isabelle Arm-Vernez, Gert Zimmer, Thomas Agoritsas, Jérôme Stirnemann, Hervé Spechbach, Idris Guessous, Silvia Stringhini, Jérôme Pugin, Pascale Roux-Lombard, Lionel Fontao, Claire-Anne Siegrist, Isabella Eckerle, Nicolas Vuilleumier, Laurent Kaiser, for the Geneva Center for Emerging Viral Diseases
medRxiv 2020.05.02.20080879; doi: https://doi.org/10.1101/2020.05.02.20080879
Validation of a commercially available SARS-CoV-2 serological Immunoassay
Benjamin Meyer, Giulia Torriani, Sabine Yerly, Lena Mazza, Adrien Calame, Isabelle Arm-Vernez, Gert Zimmer, Thomas Agoritsas, Jérôme Stirnemann, Hervé Spechbach, Idris Guessous, Silvia Stringhini, Jérôme Pugin, Pascale Roux-Lombard, Lionel Fontao, Claire-Anne Siegrist, Isabella Eckerle, Nicolas Vuilleumier, Laurent Kaiser, for the Geneva Center for Emerging Viral Diseases
medRxiv 2020.05.02.20080879; doi: https://doi.org/10.1101/2020.05.02.20080879
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2594)
- Dermatology (218)
- Emergency Medicine (390)
- Epidemiology (12131)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4026)
- Geriatric Medicine (378)
- Health Economics (670)
- Health Informatics (2604)
- Health Policy (994)
- Hematology (358)
- HIV/AIDS (830)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3793)
- Nursing (208)
- Nutrition (561)
- Oncology (1983)
- Ophthalmology (575)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (248)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1097)
- Primary Care Research (443)
- Public and Global Health (6467)
- Radiology and Imaging (1375)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (336)
- Surgery (437)
- Toxicology (51)
- Transplantation (185)
- Urology (165)